NCCN guidelines recommend that risk stratification should be based on metastatic progression, pretreatment levels of serum prostate-specific antigen (PSA), initial Gleason score, grade based on the initial biopsy, and extent of cancer involvement (clinical tumor [T] stages) (11). The gene discussed is KLK3; the disease is cancer.